ANAB Stock — AnaptysBio Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Our clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which we completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (“RA”), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (“CeD”) and eosinophilic esophagitis (“EoE”), and ANB101, a BDCA2 modulator, in a Phase 1a trial.

Source: 10-K FY2025 via SEC EDGAR

Share price

$49.00

Market cap

$1,450.8M

Cash

$286.5M

Enterprise value

$1,164.3M

Balance sheet

Cash	$286.5M
Debt	$0.0M
Net cash	$286.4M
Enterprise value	$1,164.3M
Basic shares	29.1M shares
Fully diluted shares	39.6M shares
Fully diluted market cap	$1,938.2M
Cash per share	$9.84
Quarterly burn	$25.9M
Cash runway	11.1 quarters

Cash figures as of 2026-03-31. Database snapshot: 2026-11-10.

Share structure

Common

29.1M

Pre-funded warrants

0.0M

Options

6.8M

RSUs

1.9M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

1.8M

FDSO

39.6M

Cap table as of 2026-03-31.

Price history

Loading ANAB daily closes…

Loading price history…

Next catalyst

Quimilza (imsidolimab) · Dec 12, 2026 · guided in 4 wks

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDDec 12, 2026 in 4 wks	Quimilza (imsidolimab) Generalized pustular psoriasis (GPP) PDUFA	Not disclosed	Generalized pustular psoriasis (GPP)	2026-12-12
GUIDEDFeb 1-28 in 12 wks	Jemperli (dostarlimab) AZUR-1 pivotal Phase 2 in dMMR/MSI-H locally advanced rectal cancer	Phase 2	dMMR/MSI-H locally advanced rectal cancer	February 2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Jemperli

Approved · Active Modality: antibody

Aliases dostarlimab

Target PD-1

Partnerships GSK (TESARO): collaboration & exclusive license (2014); tiered royalties + milestones; Jemperli royalties partially monetized to Sagard

Indications

Endometrial cancer (dMMR/MSI-H) (Approved)
Pan-deficient mismatch repair tumors (Approved)

Status note Royalty interest only; developed and marketed by GSK (FDA approved Apr 2021, full approval Feb 2023; chemo combo approved Jul 2023 and Aug 2024; EMA 2021/2025). Retained by ANAB post-separation; separation completed April 20, 2026.

Imsidolimab

Phase 3 · Active Modality: monoclonal antibody

Target IL-36R

Partnerships Vanda: exclusive global license (Jan 2025); royalty/milestone-bearing; milestone rights allocated to First Tracks per separation agreement

Indications

Generalized pustular psoriasis (GPP) (Phase 3)

Catalysts

— December 12, 2026

Status note IL-36R antagonist mAb. Two registration-enabling global Phase 3 trials (GEMINI-1, GEMINI-2) completed; BLA submitted Dec 2025, accepted Feb 2026. Royalty interest retained by ANAB; Vanda develops/commercializes. Separation completed April 20, 2026.

Per-asset detail extracted from the 10-Q filed 2026-05-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Rosnilimab
Lead indication	Rheumatoid Arthritis
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06041269	Phase 2	Active, not recruiting	Sponsor	ANAB	—	Rheumatoid Arthritis	—
NCT06127043	Phase 2	Active, not recruiting	Sponsor	ANAB	—	Ulcerative Colitis	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for AnaptysBio, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
EcoR1 Capital	7,880,094	no change	26.37%	2026-08-14
Tang Capital Partners	1,330,879	no change	4.08%	2026-08-14
ADAR1 Capital Management	3,698	no change	0.01%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ANAB — AnaptysBio Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

ANAB — AnaptysBio Inc.